Open Orphan plc
("Open Orphan" or the "Company")
Upcoming Scientific Presentations
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that three presentations discussing the data and learnings from recent clinical studies and projects will be presented at two upcoming conferences taking place in Belfast, Northern Ireland.
OPTIONS XI for the Control of Influenza is being held 26 - 29 September 2022 and hVIVO will be at booth 6 during the conference for potential partnering discussions. The 12th International RSV Symposium will take place on 29 September to 2 October 2022 and hVIVO will be at booth 6 during the conference for potential partnering discussions.
Details of the presentations at OPTIONS XI for the Control of Influenza are as follows:
|
Title: |
Immunomodulators and treatment of disease in the influenza human challenge model |
|
Abstract: |
AOXI0665 |
|
Date: |
Wednesday, 28 September 2022 |
|
Location: |
Hall 1, Poster Board Number: P-532 |
|
Title: |
Influenza, COVID-19, RSV and HRV: translating efficacy testing of vaccine and drugs from human challenge models to the field |
|
Abstract: |
AOXI0658 |
|
Date: |
Thursday, 29 September 2022 at 11:12 AM |
|
Session: |
Oral Abstract Session: Translational: Influenza & COVID-19 - Human challenge models |
Details of the presentation at the 12th International RSV Symposium are as follows:
|
Title: |
RSV vaccines/prophylactics: key learnings from the RSV challenge model and Efficacy of Vaccines |
|
Abstract: |
ARNI0259 |
|
Date: |
Friday, September 30, 2022 |
|
|
|
The abstracts and posters will be available on hVIVO's website from 4 October 2022 here.
For further information please contact:
|
Open Orphan plc |
+44 (0) 20 7756 1300 |
||
|
Yamin Khan, Chief Executive Officer |
|
||
|
|
|
||
|
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Phillip Marriage / |
+44 (0) 20 7933 8780 or openorphan@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / |
||
|
|
|
|
|
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is changing its name to hVIVO plc (AIM and Euronext: HVO), which is expected to take effect on the AIM market of the London Stock Exchange and the Euronext Growth Exchange market on 26 October 2022.
hVIVO is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.
The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of new models, such as malaria and COVID-19, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK and medical writing to third party clients as well as supporting the London-based challenge studies.
hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-centre studies.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach†in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
